Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seoul
Clinical trial register · South Korea

Clinical Trials in Seoul, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 55 Daegu 13 Incheon 11 Gyeonggi-do 10 Suwon Kyunggi-do 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Seoul National University Hospital183 Yonsei University143 Samsung Medical Center142 Merck Sharp & Dohme LLC111 Clear sponsor filter
Site location
Seoul55 Daegu13 Incheon11 Gyeonggi-do10 Suwon Kyunggi-do10
All 27 locations
Target enrolment
to

Trials with a site in Seoul

55 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
GlaxoSmithKline
Phase 3
690
Seoul
2026-09-08
Recruiting
GlaxoSmithKline
Phase 3
684
Seoul, Gyeonggi-do
2026-09-01
Recruiting
GlaxoSmithKline
Phase 3
800
Seoul, Seongnam-si Gyeonggi-do, Suwon Kyunggi-do
2026-07-27
Recruiting
GlaxoSmithKline
Phase 3
450
Seoul, Gyeonggi-do, Suwon Kyunggi-do
2026-06-18
Recruiting
GlaxoSmithKline
Phase 3
600
Cheongju Chungcheongbuk-do, Daegu, Seoul
2026-06-04
Recruiting
GlaxoSmithKline
Phase 2
200
Seoul, Ulsan
2026-04-15
Recruiting
GlaxoSmithKline
Phase 1/2
54
Seoul
2026-02-10
Recruiting
GlaxoSmithKline
Phase 1
83
Seoul
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
Seoul, Daegu, Seongnam-si Gyeonggi-do, Suwon Kyunggi-do, Yangsan
2025-12-03
Recruiting
GlaxoSmithKline
Phase 2
363
Busan, Incheon, Jeonju, Seoul
2025-10-30
Recruiting
GlaxoSmithKline
Phase 3
420
Changwon, Cheongju Chungcheongbuk-do, Daegu, Gyeonggi-do, Seongnam-si Gyeonggi-do, Seoul, Suwon Gyeonggi-do, Ulsan
2025-08-11
Active, closed
GlaxoSmithKline
Phase 2
168
Seoul
2025-08-06
Recruiting
GlaxoSmithKline
Phase 3
961
Daegu, Incheon, Jeonju, Seoul
2025-06-23
Recruiting
GlaxoSmithKline
Phase 1/2
451
Seoul
2025-06-11
Recruiting
GlaxoSmithKline
Phase 2
80
Seongnam-si Gyeonggi-do, Seoul
2025-06-05
Recruiting
GlaxoSmithKline
Phase 1/2
305
Seoul
2025-03-04
Recruiting
GlaxoSmithKline
Phase 3
520
Hwasun, Jeonju, Seoul, Ulsan
2024-12-16
Active, closed
GlaxoSmithKline
Phase 1/2
14
Daegu, Gyeonggi-do, Seoul
2024-12-13
Recruiting
GlaxoSmithKline
Phase 3
514
Bucheon Kyunggi-Do, Seoul, Suwon Kyunggi-do, Yongsan-Ku Seoul
2024-12-12
Active, closed
GlaxoSmithKline
Phase 2
283
Ansan, Busan, Pusan, Seoul
2024-11-11
Recruiting
GlaxoSmithKline
Phase 1
845
Gyeonggi-do, Seoul
2024-09-30
Recruiting
GlaxoSmithKline
Phase 2
393
Ansan, Bucheon-si, Daegu, Seoul, Suwon Gyeonggi-do
2024-09-27
Recruiting
GlaxoSmithKline
Phase 3
440
Bucheon Kyunggi-Do, Seoul, Suwon Kyunggi-do, Yongsan-Ku Seoul
2024-09-11
Active, closed
GlaxoSmithKline
Phase 3
10,212
Seoul, Ansan, Bucheon-si Kyunggi-do 14584, Daegu, Incheon, Jeonju, Kangwon-do, Suwon Gyeonggi-do
2024-08-01
Recruiting
GlaxoSmithKline
Phase 3
150
Jeonju, Seoul
2024-07-19
Recruiting
GlaxoSmithKline
Phase 1
675
Gyeonggi-do, Seoul
2024-07-02
Active, closed
GlaxoSmithKline
Phase 3
88
Daegu, Incheon, Seoul
2024-06-10
Active, closed
GlaxoSmithKline
Phase 4
1,358
Busan, Daegu, Seongnam-si Gyeonggi-do, Seoul, Suwon Kyunggi-do
2024-04-16
Recruiting
GlaxoSmithKline
Phase 3
864
Busan, Pusan, Seoul, Suwon Gyeonggi-do
2024-03-21
Active, closed
GlaxoSmithKline
Phase 2
316
Daegu, Seongnam-si Gyeonggi-do, Seoul, Suwon Kyunggi-do
2023-11-14
Active, closed
GlaxoSmithKline
Phase 4
50
Incheon, Junggu, Kyungki-do, Seongnam-si Gyeonggi-do, Seoul
2023-11-10
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Seoul, Suwon Kyunggi-do
2023-09-13
Recruiting
GlaxoSmithKline
Phase 3
892
Daegu, Gyeonggi-do, Seoul
2023-08-01
Recruiting
GlaxoSmithKline
Phase 1/2
123
Seoul
2023-06-14
Recruiting
GlaxoSmithKline
Phase 3
138
Cheongju Chungcheongbuk-do, Gwangju, Seoul
2023-04-24
Active, closed
GlaxoSmithKline
Phase 2
154
Seoul
2023-04-03
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Incheon, Seoul, Yongsan-Ku Seoul
2023-01-02
Active, closed
GlaxoSmithKline
Phase 2
351
Incheon, Seoul, Suwon Gyeonggi-do
2022-10-14
Recruiting
GlaxoSmithKline
Phase 3
109
Gwangju, Jeonju, Kangwondo, Seoul, Suwon Kyunggi-do
2022-09-06
Active, closed
GlaxoSmithKline
Phase 1/2
14
Seoul, Ulsan
2022-08-31
Active, closed
GlaxoSmithKline
Phase 3
3,038
Ansan, Bucheon-si, Incheon, Kangwon-do, Seoul
2022-08-10
Active, closed
GlaxoSmithKline
Phase 1/2
20
Seoul, Ulsan
2022-07-19
Active, closed
GlaxoSmithKline
Phase 3
163
Gwangju, Seoul
2022-07-14
Active, closed
GlaxoSmithKline
Phase 1
152
Seoul
2022-03-22
Active, closed
GlaxoSmithKline
Phase 2
360
Ansan-si Gyenggi-do, Busan, Pusan, Seoul
2021-12-14
Active, closed
GlaxoSmithKline
Phase 1/2
30
Seoul, Ulsan
2021-07-29
Active, closed
GlaxoSmithKline
Phase 2/3
758
Cheongju Chungcheongbuk-do, Daegu, Gyeonggi-do, Pusan, Seongnam-si Gyeonggi-do, Seoul, Suwon Kyunggi-do
2020-12-08
Active, closed
GlaxoSmithKline
Phase 1
36
Busan, Seoul
2020-10-09
Active, closed
GlaxoSmithKline
Phase 3
302
Gyeonggi-do, Hwasun, Inchon, Seoul
2020-10-01
Active, closed
GlaxoSmithKline
Phase 1
107
Seoul
2020-06-25
Active, closed
GlaxoSmithKline
Phase 1/2
106
Incheon, Seoul, Ulsan
2020-06-08
Active, closed
GlaxoSmithKline
Phase 3
325
Gyeonggi-do, Hwasun, Incheon, Seongnam-si Gyeonggi-do, Seoul
2020-04-02
Active, closed
GlaxoSmithKline
Phase 1
118
Seoul
2019-12-18
Active, closed
GlaxoSmithKline
Phase 1/2
208
Incheon, Seoul
2019-10-07
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Busan, Daegu, Seoul
2018-05-03
Rows per page Showing 1–55 of 55
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seoul

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 55 of those studies with a site in Seoul that also match the filters currently applied.

How many clinical trials are recruiting in Seoul?

28 of the 55 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Seoul), 55 studies
PhaseStudiesRecruitingShare
Phase 3221640%
Phase 212421.8%
Phase 1/210418.2%
Phase 17312.7%
Phase 2/3213.6%
Phase 4203.6%

Most active sponsors

Lead sponsors with the most studies (Seoul)
Lead sponsorStudiesRecruiting
GlaxoSmithKline5528
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.